Genetic Analysis summarizes a successful year
OSLO, NORWAY – 21 December 2021: 2021 has been an eventful year for Genetic Analysis (“GA” or “the Company”), in which the Company made strong progress in a market that is developing both fast and positively. The past year has been filled with important milestones like the signing of a new high-volume lab in Europe, oversubscribed IPO, successful listing at Spotlight Stock Market and the receival of a research grant of NOK 16 million to develop a new IBD test. GA has now entered an exciting new phase of its commercial journey as a listed company.CEO Ronny Hermansen comments“The global